On November 14, Viking Therapeutics rose 5.47% in Regular Trading, trading near $29.14 per share, with turnover of $60.36 million.
The move coincided with the company saying it will present two VK2735 posters at ObesityWeek, adding to recent pipeline updates that have kept investor focus on its obesity program.
Earlier, Viking Therapeutics said it had started a phase 3 program for oral VK2735 in adults with obesity, including separate studies in patients with and without type 2 diabetes, with percent change in body weight after 68 weeks as the primary endpoint. The company also recently initiated a maintenance-dosing trial evaluating oral and additional subcutaneous VK2735 regimens after initial weight loss. In its latest quarterly update, Viking Therapeutics reported EPS of -1.55 and said cash, cash equivalents, and short-term investments were about $960 million.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments